PATENT CLAIM ANALYSIS

Application Number: 15747874
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "001610"]

Abstract:
The present invention relates to combinations of at least two components, component A and component B, component A being an immune checkpoint inhibitor, and component B being a pharmaceutically acceptable salt of the alkaline-earth radio nuclide radium-223, the combination being useful for the treatment or prophylaxis of cancer.

Claim (Index 6):
The combination according to  claim 2 , in which component A is an anti-CTLA-4 antibody.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 86.0
- Lexical Diversity: 1.39474
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15101540', '15101638', '15506316', '15490535', '15115730']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6757743441807038
- 35 USC 102 Novelty (BERT): 0.5274422438501515
- Combined Prediction Score: 0.6609411341476485
- Mean Citation Score: 250.10738
- Max Citation Score: 284.9628600000001
- Similarity Product: 169.505215663848

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test